drugset / Trial / NCT05177718
Natalizumab and Chronic Inflammation
NaSingle-groupOpen-labelTreatment
Summary
In this study the investigators will assess the ability of Natalizumab, a medication given to treat multiple sclerosis (MS), to restore blood brain barrier integrity and repair subtle leakages of the blood brain barrier (BBB).
Timeline
- Start
- 2022-09-16
- Primary completion
- 2023-04-05
- Completion
- 2023-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | natalizumab | Monoclonal antibody | 300 mg | Intravenous |